Lorlatinib‐Containing Therapy for MYCN ‐Amplified, ALK ‐Mutated Neuroblastoma With Bulky Leptomeningeal Relapse: A Case Report
Pediatric Blood & Cancer · 29.10.2026
DOI: 10.1002/1545-5017.70790 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 29.10.2026. Verfasst von Jinwoo Kim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu, South Korea. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Central nervous system (CNS) relapse of neuroblastoma carries a poor prognosis, and craniospinal irradiation (CSI) poses substantial long‐term toxicity in young children. We report a toddler with MYCN ‐amplified neuroblastoma harboring somatic ALK R1275Q who developed extensive leptomeningeal relapse with paraplegia. Lorlatinib‐containing chemotherapy resulted in near‐complete resolution of leptomeningeal disease and full neurologic recovery. Although subsequent CNS recurrence was confirmed and ultimately prompted CSI, the initial response permitted its deferral for 11 months. This case highlights the potential of lorlatinib‐containing therapy to reduce CNS tumor burden and serve as a bridging strategy to CSI despite concurrent MYCN amplification.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu, South Korea.
- Pediatric Hematology/Oncology, Kyungpook National University Children's Hospital, Daegu, South Korea.
- Department of Radiology, School of Medicine, Kyungpook National University, Daegu, South Korea.
- Department of Neurosurgery, School of Medicine, Kyungpook National University, Daegu, South Korea.
- Department of Radiation Oncology, School of Medicine, Kyungpook National University, Daegu, South Korea.
ORCID-Profile: Jinwoo Kim, Sung Eun Kim, Ji Yoon Kim, Ki-Su Park, Ye Jee Shim
Zitieren
APA
Kim, J., Kim, M., Jung, N., Kim, S. E., Kim, J. Y., Chu, M. A., Kwon, J. E., Kim, Y. H., Lee, S. M., Park, K. S., Lee, J. E., & Shim, Y. J. (2026). Lorlatinib‐Containing Therapy for MYCN ‐Amplified, ALK ‐Mutated Neuroblastoma With Bulky Leptomeningeal Relapse: A Case Report. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70790
Vancouver
Kim J, Kim M, Jung N, Kim SE, Kim JY, Chu MA, et al. Lorlatinib‐Containing Therapy for MYCN ‐Amplified, ALK ‐Mutated Neuroblastoma With Bulky Leptomeningeal Relapse: A Case Report. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70790
BibTeX
@article{Kim2026,
author = {Kim, Jinwoo and Kim, Minji and Jung, Nani and Kim, Sung Eun and Kim, Ji Yoon and Chu, Mi Ae and Kwon, Jung Eun and Kim, Yeo Hyang and Lee, So Mi and Park, Ki-Su and Lee, Jeong Eun and Shim, Ye Jee},
title = {Lorlatinib‐Containing Therapy for MYCN ‐Amplified, ALK ‐Mutated Neuroblastoma With Bulky Leptomeningeal Relapse: A Case Report},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/1545-5017.70790}
}
EUVIMED